Novo Nordisk (NVO) Stock: Surges as Haemophilia Drug Nears EU Approval

TLDR Novo Nordisk stock climbs 2.83% after CHMP backs FREHEMGO for EU approval plans. FREHEMGO targets haemophilia A with weekly, biweekly, or monthly dosing options. FRONTIER trials showed low bleeding rates across adult and child patient groups. Novo plans first European FREHEMGO launches during the fourth quarter of 2026. US regulators are also reviewing denecimig [...]

The post Novo Nordisk (NVO) Stock: Surges as Haemophilia Drug Nears EU Approval appeared first on Blockonomi.